Biotech – the red-hot, high risk investment story

University challenge

How to profit from Britain's innovation explosion

  • Why creative destruction works

Biotech - the red-hot, high risk investment story

Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.

Invest in cutting-edge healthcare

Max King looks at one fund allowing investors to put their money in cutting-edge medical research.

The pharma price-gouging scandal

Pharmaceutical companies have hit the headlines for hiking prices for life-saving drugs by shocking amounts. What’s going on? Simon Wilson reports.

The race to commercialise our DNA

The race to development and sell gene-editing procedures will be as exciting as the race into space, says Nick O’Connor.

Three promising sectors for 2017

Max King tips a host of funds in various sectors to do well in the forthcoming year.

Lilly fails Alzheimer’s test

Eli Lilly’s new treatment has proved ineffective in late-stage trials – yet another blow for a struggling sector, says Ben Judge.

Who will prosper under Trump?

Now that the markets have got over the shock of a Trump victory in the US presidential election, David C Stevenson looks at which funds to buy.

Earn a 3.5% yield from healthcare

David C Stevenson looks at the best healthcare and biotech investment trusts to tuck away in your portfolio.

Novo Nordisk: Pharma giant takes a tumble

Novo Nordisk shocked investors by slashing its growth forecasts. The new CEO faces a tough start, says Ben Judge.

Neoevolution with gene-editing

Gene-editing puts mankind in control of its own evolution. People are going to become increasingly creative with this technology, says Nick O’Connor.

The wrath of man

Mankind continues to push back the boundaries of what is medically possible, says Nick O’Connor. It is quite possibly the greatest undertaking in human history.

Showing page 1 of 9
66% off newsstand price

12 issues (and much more) for just £12

That’s right. We’ll give you 12 issues of MoneyWeek magazine, complete access to our exclusive web articles, our latest wealth building reports and videos as well as our subscriber-only email… for just £12.

That’s just £1 per week for Britain’s best-selling financial magazine.

Click here to take advantage of our offer

Britain is leaving the European Union. Donald Trump is reducing America’s role in global markets. Both will have profound consequences for you as an investor.

MoneyWeek analyses the critical issues facing British investors on a weekly basis. And, unlike other publications, we provide you with the solutions to help you turn a situation to your financial advantage.

Take up our offer today, and we’ll send you three of our most important investment reports:

All three of these reports are yours when you take up our 12 issues for £12 offer today.

MoneyWeek has been advising private British investors on what to do with their money since 2000. Our calls over that period have enabled our readers to both make and save a great deal of money – hence our position as the UK’s most-trusted investment publication.

Click here to subscribe for just £12